申请人:GLAXO GROUP LIMITED
公开号:EP0403261A2
公开(公告)日:1990-12-19
The invention provides amide derivatives of the general formula (I)
wherein R¹ is a hydrogen atom or a C₁₋₆alkyl group;
Y represents a group -(CH₂)m-, where m represents 2, 3 or 4 or a group -X(CH₂)p, where p represents 2 or 3, X represents an oxygen or a sulphur atom or a group NR⁵, where R⁵ is a C₁₋₆alkyl group, and X is attached to the benzene ring moiety of the molecule; and
Im represents an imidazolyl group of the formula:
wherein one of the groups represented by R², R³ and R⁴ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C₁₋₆alkyl group;
and physiologically acceptable salts and solvates thereof.
The compounds of formula (I) are potent and selective antagonists of 5-hydroxytryptamine at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
本发明提供通式(I)的酰胺衍生物
其中 R¹ 是氢原子或 C₁₋₆ 烷基;
Y 代表基团-(CH₂)m-,其中 m 代表 2、3 或 4 或基团-X(CH₂)p,其中 p 代表 2 或 3,X 代表氧原子或硫原子或基团 NR⁵,其中 R⁵ 是 C₁₋₆烷基,且 X 连接到分子的苯环分子上;以及
Im 代表式中的咪唑基团:
其中 R²、R³ 和 R⁴ 所代表的基团之一是氢原子或 C₁₋₆烷基、C₃₋₇环烷基、C₃₋₆烯基、苯基或苯基 C₁₋₃烷基,而另外两个基团(可以相同或不同)分别代表氢原子或 C₁₋₆烷基;
及其生理上可接受的盐类和溶剂。
式 (I) 化合物是 5-HT₃ 受体上 5- 羟色胺的强效选择性拮抗剂,可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。